Scholarlink

Purpose <p>The optimal time point of salvage radiotherapy (sRT) for biochemical recurrence (BCR) following radical prostatectomy is still under debate. Current European guidelines recommend salvage intensity-modulated and image‐guided radiotherapy for men with two consecutive PSA rises. However, no specific PSA threshold for initiation time is recommended. Nonetheless, lower PSA level may be associated with better cancer-control outcomes.</p> Methods <p>Relying on the University Cancer Center Frankfurt database, we evaluated differences in metastasis-free survival (MFS) among patients treated with early sRT (&lt; 0.5 ng/ml) vs. sRT at PSA ≥ 0.5ng/ml. Subgroup analyses addressed sRT patients with high-risk features for indication of adjuvant radiation therapy, including Gleason score 8–10 and/or pT3–4 stage and/or pN1.</p> Results <p>Of 190 sRT patients, 69% received early sRT at median PSA 0.24ng/ml vs. 0.89ng/ml. MFS was significantly better for early sRT patients, relative to sRT at PSA &gt; 0.5 ng/ml (hazard ratio [HR]: 8.44, <i>p</i> &lt; 0.01). Similarly, sRT patients with high-risk features also had significant better MFS at sRT with PSA &lt; 0.5ng/ml (HR: 12.69, <i>p</i> &lt; 0.01). After additional multivariable adjustment, early sRT at PSA &lt; 0.5ng/ml was independently associated with better MFS outcomes for all patients (HR: 8.2) and high-risk sRT subgroups (HR: 55.6, both <i>p</i> &lt; 0.05). Finally, we validated the initiation of sRT at an even lower cut-off of a PSA level ≤ 0.25ng/ml. However, this did not result in a significantly different outcomes, probably due to sample size limitations.</p> Conclusion <p>Our results validate European guidelines’ recommendation to initiate sRT at low PSA levels &lt; 0.5ng/ml providing better MFS, especially in patients with high-risk features, refusing adjuvant radiation therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Influence of PSA level at salvage radiotherapy on metastasis-free survival following radical prostatectomy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月21日

查看全文
  • Mike Wenzel,
  • Benedikt Lauer,
  • Kathrin Burdenski,
  • Nikolaos Tselis,
  • Claus Rödel,
  • Christian Brandts,
  • Marit Ahrens,
  • Jens Köllermann,
  • Markus Graefen,
  • Clara Humke,
  • Carolin Siech,
  • Benedikt Hoeh,
  • Felix K. H. Chun,
  • Philipp Mandel

摘要

Purpose

The optimal time point of salvage radiotherapy (sRT) for biochemical recurrence (BCR) following radical prostatectomy is still under debate. Current European guidelines recommend salvage intensity-modulated and image‐guided radiotherapy for men with two consecutive PSA rises. However, no specific PSA threshold for initiation time is recommended. Nonetheless, lower PSA level may be associated with better cancer-control outcomes.

Methods

Relying on the University Cancer Center Frankfurt database, we evaluated differences in metastasis-free survival (MFS) among patients treated with early sRT (< 0.5 ng/ml) vs. sRT at PSA ≥ 0.5ng/ml. Subgroup analyses addressed sRT patients with high-risk features for indication of adjuvant radiation therapy, including Gleason score 8–10 and/or pT3–4 stage and/or pN1.

Results

Of 190 sRT patients, 69% received early sRT at median PSA 0.24ng/ml vs. 0.89ng/ml. MFS was significantly better for early sRT patients, relative to sRT at PSA > 0.5 ng/ml (hazard ratio [HR]: 8.44, p < 0.01). Similarly, sRT patients with high-risk features also had significant better MFS at sRT with PSA < 0.5ng/ml (HR: 12.69, p < 0.01). After additional multivariable adjustment, early sRT at PSA < 0.5ng/ml was independently associated with better MFS outcomes for all patients (HR: 8.2) and high-risk sRT subgroups (HR: 55.6, both p < 0.05). Finally, we validated the initiation of sRT at an even lower cut-off of a PSA level ≤ 0.25ng/ml. However, this did not result in a significantly different outcomes, probably due to sample size limitations.

Conclusion

Our results validate European guidelines’ recommendation to initiate sRT at low PSA levels < 0.5ng/ml providing better MFS, especially in patients with high-risk features, refusing adjuvant radiation therapy.